Day: June 4, 2022

HII Christens National Security Cutter Calhoun (WMSL 759)

HII Christens National Security Cutter Calhoun (WMSL 759)

NSC Calhoun Bottle Break Ship’s Sponsor Mrs. Christina Calhoun Zubowicz christened the U.S. Coast Guard’s 10th national security cutter Calhoun (WMSL 759) at HII’s Ingalls Shipbuilding division. NSC 10 Calhoun is named for Zubowicz’s grandfather, Charles L. Calhoun, the first Master Chief Petty Officer of the Coast Guard. Also pictured are Commandant of the Coast Guard, Adm. Linda Fagan, Master Chief Petty Officer of the Coast Guard Heath Jones, Ingalls Shipbuilding President, Kari Wilkinson, and Capt. Timothy Sommella, prospective commanding officer, Calhoun. PASCAGOULA, Miss., June 04, 2022 (GLOBE NEWSWIRE) — HII (NYSE: HII) christened Legend-class national security cutter Calhoun (WMSL 759) today at the company’s Ingalls Shipbuilding division. Calhoun (WMSL 759) is named to honor Charles L. Calhoun, the first master...

Continue reading

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremia Data presented as oral late breaker at American Transplant Congress BK Virus is a leading cause of transplant loss and transplant-associated morbidity; currently no approved treatments BRISBANE, Calif., June 04, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus (BKV) in kidney transplant patients showed that MAU868 was well tolerated and demonstrated significant BK antiviral activity in kidney transplant recipients with BK viremia. These data were delivered...

Continue reading

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with T1D HIGH POINT, N.C., June 04, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that the results from the JDRF-supported mechanistic study assessing effects of TTP399 on ketones during acute insulin withdrawal were published in the Diabetes Obesity and Metabolism journal and presented at The American Diabetes Association’s 82nd Scientific Sessions (#ADA2022) on June 5th. This Phase 1, mechanistic study evaluated the effects of the GKA TTP399 on ketoacidosis risk in individuals with T1D on insulin pump therapy. The primary...

Continue reading

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and function, thereby increasing insulin levels and controlling high glucose levels BMF-219, a covalent menin inhibitor, showed strong, prolonged glycemic control, insulin sensitization, and hemoglobin A1C (HbA1c) reduction in the streptozotocin (STZ) beta-cell ablation and zucker diabetic fatty (ZDF) rat models while on drug and after washout, outperforming an agent used as standard of care Biomea plans to initiate a Phase I/II clinical trial of BMF-219 in type 2 diabetes in the second half of 2022, subject to investigational new drug (IND) submission and clearance Company to host virtual investor R&D event on Monday, June 6, 2022 at 4:05 PM EDT featuring BMF-219’s potential to treat type 2 diabetes, including...

Continue reading

VGP NV: Upcoming Inclusion in the FTSE EPRA Nareit Developed Europe Index

VGP NV: Upcoming Inclusion in the FTSE EPRA Nareit Developed Europe Index

PRESS RELEASE Regulated Information 4 June 2022, 07:00 CET, Antwerp, Belgium: VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, announced that its share has been admitted to the FTSE EPRA Nareit Developed Europe Index in the FTSE EPRA Nareit Global Real Estate Index Series (“Developed Europe Index”). Its inclusion will be effective from the start of trading on Monday the 20th of June 2022. The admittance to the Developed Europe Index follows VGP’s inclusion in the FTSE EPRA Nareit Global Emerging Index on the 23rd of September 2019. The eligibility for the Developed Europe Index is dependent of a company’s market capitalization, the liquidity and free float of the share and the geographical location of the portfolio. In March of this year VGP was also included in Euronext Brussels’...

Continue reading

<div>Victory Square Technologies Reports Full Year 2021 Financial Results & 2021 Recap</div>

Victory Square Technologies Reports Full Year 2021 Financial Results & 2021 Recap

2021 unaudited Net Asset Value (“NAV”) increased to $102,269,229 from $51,258,000 in 2020 VANCOUVER, British Columbia, June 03, 2022 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that provides VC Investment access to a diverse portfolio of next generation technology companies within an audited, transparent and liquid investment vehicle, announces it has filed its its Audited Annual Consolidated Financial Statements for the year ended December 31st, 2021 along with its Management Discussion and Analysis (MD&A) on Friday, June 3rd, 2022. The decline in the capital markets over the past 12 months has been brutal, volatility on the major indexes, inflation worries, rate hikes, and the Russia-Ukraine Crisis have created a lot of uncertainty about...

Continue reading

Grupo Aeroportuario del Pacifico Reports in May 2022 a Passenger Traffic Increase of 15.3% Compared to 2019 (Increase of 23.2% Compared to 2021)

Grupo Aeroportuario del Pacifico Reports in May 2022 a Passenger Traffic Increase of 15.3% Compared to 2019 (Increase of 23.2% Compared to 2021)

GUADALAJARA, Mexico, June 03, 2022 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for the month of May 2022, which includes comparisons with the 2019 and 2021 figures to facilitate the reading and understanding of the passenger traffic trend. For May 2022, the total number of terminal passengers at GAP’s 12 Mexican airports increased by 13.7%, compared to the same period of 2019. Puerto Vallarta, Tijuana, Los Cabos and Guadalajara airports presented an increase in passenger traffic of 35.0%, 32.6%, 27.2% and 1.3%, respectively, compared to May 2019. On the other hand, it is important to highlight that the Montego Bay airport presented a passenger traffic decrease of only 0.1% compared to 2019. Passenger...

Continue reading

The Limestone Boat Company Limited Announces Closing of Its Previously Announced Non-brokered Private Placement Offering of 10% Unsecured Convertible Debentures

The Limestone Boat Company Limited Announces Closing of Its Previously Announced Non-brokered Private Placement Offering of 10% Unsecured Convertible Debentures

Capital infusion into the Company aims to further increase near-term production throughput to meet the growing backlog and increased demand for both its Limestone and Aquasport Brands through 2023. NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. COLLINGWOOD, Ontario, June 03, 2022 (GLOBE NEWSWIRE) — The Limestone Boat Company Limited (“Limestone” or the “Company“) (TSXV: BOAT |OTCQB: LMSBF) is pleased to announce the closing of its previously announced non-brokered private placement of 10% unsecured convertible debentures of the Company (“Debentures“) at a price of $1,000 per Debenture for aggregate gross proceeds of approximately $500,000 (the “Offering“). As previously disclosed, $244,000 of the Debentures issued in connection...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.